Showing results (11-20 of 22) with videos related to

Sort By:
Pageof 3
Pharmacology Research & Perspectives|October 31, 2015
Modeling effects of dexamethasone on disease progression of bone mineral density in collagen-induced arthritic ratsHoi-Kei Lon, Debra C DuBois, Justin C Earp, et al.
Pharmaceutical Research|March 2, 2011
Pharmacokinetic-pharmacodynamic disease progression model for effect of etanercept in Lewis rats with collagen-induced arthritisHoi-Kei Lon, Dongyang Liu, Qi Zhang, et al.
Clinical Pharmacology in Drug Development|July 28, 2018
Pharmacokinetics, Safety, Tolerability, and Pharmacodynamics of Alicapistat, a Selective Inhibitor of Human Calpains 1 and 2 for the Treatment of Alzheimer Disease: An Overview of Phase 1 StudiesHoi-Kei Lon, Nuno Mendonca, Sandra Goss, et al.
Targeted Oncology|August 18, 2025
Population Exposure-Response Efficacy Analysis of Elranatamab (PF-06863135) in Patients with Multiple MyelomaHoi-Kei Lon, Jennifer Hibma, Sibo Jiang, et al.
Biopharmaceutics & Drug Disposition|March 5, 2013
Pharmacokinetics, pharmacodynamics and toxicities of methotrexate in healthy and collagen-induced arthritic ratsDong-Yang Liu, Hoi-Kei Lon, Yan-Lin Wang, et al.
Clinical Pharmacokinetics|May 26, 2026
Population Pharmacokinetic Analysis of Glecaprevir and Pibrentasvir in Pediatric Patients ≥ 3 to < 18 Years of Age with Genotypes 1-6 Chronic Hepatitis C Virus (HCV) InfectionNeha Thakre, Denise Beck, Ahmed M Saeed, et al.
Clinical and Translational Science|April 29, 2026
Elranatamab: Mechanism of Action, Clinical, and Translational ScienceMohamed Elmeliegy, Andrea Viqueira, Erik Vandendries, et al.
Journal of Pharmacokinetics and Pharmacodynamics|July 22, 2023
International society of Pharmacometrics Mentorship Program (IMP): feedback survey from the first cohort of mentor-mentee pairsPatrick O Hanafin, Ananya Murthy, Dhananjay Marathe, et al.
Targeted Oncology|February 25, 2025
Dose Optimization of Elranatamab to Mitigate the Risk of Cytokine Release Syndrome in Patients with Multiple MyelomaMohamed Elmeliegy, Andrea Viqueira, Erik Vandendries, et al.
The Lancet. Neurology|February 20, 2021
Safety and efficacy of tilavonemab in progressive supranuclear palsy: a phase 2, randomised, placebo-controlled trialGünter U Höglinger, Irene Litvan, Nuno Mendonca, et al.
Pageof 3